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Background: Perioperative blood transfusions have been associated with poor clinical outcomes in the context of
oncological surgery. Current literature is inconclusive whether blood transfusions are linked to shorter recurrence
free and overall survival after lung cancer surgery. We hypothesize that blood transfusions in patients undergoing
surgery for non-small cell lung cancer are associated with poor oncological survival.
Methods: After IRB approval, perioperative data from 636 patients who underwent lung cancer surgery was
collected. Patients were evaluated for time to tumor recurrence and overall survival.
Results: 60 patients were transfused and 576 subjects were not. Patients who received transfusion were more likely
to have more advanced disease (p = 0.018), and preoperative low hemoglobin concentrations (p < 0.0001)
compared to non-transfused patients. In the multivariable Cox regression analysis, blood transfusion was associated
with a significant reduction in recurrence free survival (p = 0.025), HR: 1.55 (95% CI: 1.06-2.27) and overall survival
(p = 0.0002) HR: 2.04 (95% CI: 1.41-2.97). However, analysis after propensity score matching between the two groups
revealed that the effect of blood transfusion was significant for reduction in overall survival (p = 0.0356), HR: 1.838
(95% CI: 1.04-3.22) but not for recurrence free survival (p = 0.1460), HR: 1.493 (95% CI: 0.87-2.56).
Conclusions: Perioperative administration of red blood cells appears be associated with a decreased overall survival
but not recurrence free survival after lung cancer surgery. Our study has the limitations of a retrospective review.
Hence, our results should be confirmed by a prospective randomized control trial.Background
Surgery remains the most effective treatment for stage I to
IIIa non-small cell lung cancer (NSCLC), which is the sec-
ond most common cancer in the United States [1]. Al-
though the rate of perioperative blood transfusions in
patients with NSCLC is relatively low, the number of pa-
tients who will receive packed red blood cells (pRBCs)
across the world during surgery for NSCLC is not insig-
nificant and hence their exposition to adverse effects of
blood transfusions [2,3]. Unfortunately, administration
of pRBCs is associated with a distinct pathology of im-
munosuppression, known as transfusion related immune* Correspondence: jcata@mdanderson.org
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reproduction in any medium, provided the orsuppression (TRIM). TRIM has been linked to a number
of complications including effects on cancer recurrence
[4]. TRIM is considered to contribute to progression of
minimal residual disease (MRD) to clinical metastasis par-
ticularly in patients who do not receive postoperative
chemo-radiation as adjuvant therapy after surgery [5-9].
Several mechanisms have been described to be responsible
of TRIM. The accumulation of tumor growth factors, lyso-
phophatidylcholines and pro-tumoral cytokines in the
units of pRBCs along with a predominant immunosup-
pressive response of the host in reaction to microparticles
and fragmented RBCs facilitate the growth of cancer cells
[10]. Moreover, patients undergoing lung cancer surgery
have significant impairment in their ability to attack can-
cer cells as the result of cancer itself, surgery, anesthetics
and analgesics given intra- and postoperatively [11]. Thus,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients after surgery.
The results of a Cochrane review indicate that blood
transfusions are associated with an increased risk of cancer
recurrence in patients with colorectal cancer [12]. Several
retrospective studies in patients with NSCLC demonstrated
that perioperative blood transfusions were associated with
poorer disease-free and overall survival [2,13-15]. However,
other studies have concluded to the contrary [16,17]. The
published retrospective studies had several limitations in-
cluding small sample size, differences in the surgical proce-
dures performed, differences in the type of blood products
administered, differences in the follow-up duration and the
presence of confounding tumor and treatment related fac-
tors [14,15,17]. Thus, we decided to investigate whether the
administration of pRBCs to patients with stage 1–3 NSCLC
who underwent tumor resection at MD Anderson Cancer




After approval from MD Anderson Cancer Center institu-
tional review board, we recorded information from 636 pa-
tients with stage 1-3a NSCLC cancer who underwent
lobectomies, sublobar resection, sleeve lobectomy, or
pneumonectomy from 2004 through 2006. Patients who
received allogenic pRBCs within 30 days before surgery
and during their postoperative hospitalization were com-
pared with those who received no transfusion. We col-
lected demographic (age, gender, body mass index and
ASA physical status), co-morbidities (smoking, alcohol
consumption, diabetes mellitus, coronary artery disease,
creatinine higher than 2 mg/dL, stroke, and preopeative
anemia defined as hemoglobin lower than 12 g/dL),
tumor-related variables (tumor size and stage) and treat-
ment-related variables (preoperative and postoperative
chemotherapy and radiation). We also recorded the num-
ber of pRBCs units transfused.
Statistical analysis
The primary endpoint of interest was recurrence free sur-
vival (RFS), defined as the time in months from surgery to
recurrence or death, whichever event occurred first. Overall
survival (OS) was defined as the time in months from sur-
gery to death from any cause. The exposure variable of
interest was blood transfusion status (yes or no) for surgery.
Other prognostic variables of interest included age at sur-
gery, gender, BMI, ASA, cancer stage, tumor size, smoking
status, alcohol consumption, patient comorbidities, pre-
operative hemoglobin level, preoperative and postoperative
chemoradiation.
Propensity score analysis was undertaken in an at-
tempt to adjust for potential bias associated with factorsrelated to the decision to undergo blood transfusion.
This statistical methodology has often been used in ob-
servational studies to control for nonrandom treatment
assignment of patients by adjusting for differences in
covariates between the treatment groups. To control for
factors that may confound the relationship between
blood transfusion and RFS or OS, we determined the
propensity score to receive blood transfusion for each
patient, using multivariable logistic regression. The co-
variates included in the analysis were: age at surgery,
gender (F or M), BMI, ASA (2, 3, or 4), stage (1, 2, or 3),
and preoperative hemoglobin level. Given the propen-
sity scores for all patients, we identified sets of patients,
one transfused patient randomly matched with two who
did not undergo blood transfusion, using a 5-to-1 digit
greedy match algorithm. The differences in propensity
scores in each set were no more than 0.06. We used ab-
solute standardized differences to assess balance in the
baseline variables between patients who underwent
blood transfusion and those who did not undergo blood
transfusion in the matched cohort. The absolute stan-
dardized differences for all baseline covariates were
< 9% in the matched cohort.
For the prematching cohort, differences in demo-
graphic, clinical, and tumor characteristics between
groups of patients who underwent blood transfusion
and those who did not undergo blood transfusion were
compared by using Fisher’s exact test or Chi-square test
for categorical variables and Wilcoxon rank sum test
for continuous variables. Kaplan-Meier method was
used to evaluate the effect of patient characteristics on
RFS and OS. Multivariable Cox proportional hazards
models were used to determine the effect of blood
transfusion on RFS and OS after adjusting for the prog-
nostic variables.
To get the matched cohort, 37 patients were excluded
due to missing information on RFS, where 9 of them
were transfused patients. One of the remaining 51
transfused patients did not have a match and five of the
51 transfused patients did not have a second match in
the non-transfused group (Table 1). For the matched
cohort (n = 135), differences in demographic, clinical,
and tumor characteristics between matched pairs
were evaluated using generalized estimating equation
method. Cox proportional hazards models stratified on
the matched pairs were fitted to determine the effect of
blood transfusion on RFS and OS for the matched co-
hort. Kaplan-Meier curves by transfusion status were
generated for the prematching cohort and the matched
cohort. All tests were 2-sided. P values < 0.05 were con-
sidered statistically significant. All analyses were con-
ducted using SAS (version 9.1; SAS Institute, Cary, NC)
and S-plus (version 8.0; TIBCO Software Inc., Palo Alto,
California) statistical software.
Table 1 Patient and tumor characteristics by blood transfusion status before and after matching
Factors All patients P value Matched patients P value
Non-transfused Transfused Non-transfused Transfused
Total n 576 (90.6%) 60 (9.4%) 90 45
Age (SD) 65.16 (10.54) 66.21 (9.46) 0.91 65.08 (10.8) 65.8 (10.12) 0.73
BMI (SD) 27.06 (5.31) 26.88 (7.33) 0.15 27.37 (5.76) 27.02 (7.59) 0.79
Gender 0.43 0.80
Female 267 (89.6%) 31 (10.4%) 48 (67.6%) 23 (32.4%)
Male 309 (91.4%) 29 (8.6%) 42 (65.6%) 22 (34.4%)
ASA 0.48 0.82
2 62 (93.9%) 4 (6.1%) 9 (75%) 3 (25%)
3 480 (90.4%) 51 (9.6%) 75 65.8%) 39 (34.2%)
4 33 (86.8%) 5 (13.2%) 6 (66.7%) 3 (33.3%)
Stage 0.01 0.92
1 328 (93.4%) 23 (6.6%) 32 (65.3%) 17 (34.7%)
2 115 (87.8%) 16 (12.2%) 25 (65.8%) 13 (34.2%)
3 131 (86.2%) 21 (13.8%) 33 (68.8%) 15 (31.3%)
Hb g/dL, (SD) 13.43 (1.42) 12.08 (1.58) < 0.0001 12.4 (1.3) 12.3 (1.4) 0.73
A p value < 0.05 was considered statistically significant. BMI Body mass index. ASA American Society of Anesthesiologist physical status. Hb Hemoglobin.
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Patient characteristics
We used a total of 636 patients in our analysis, 60 in the
blood transfusion group, and 576 in the no-tranfusion
group. The median follow-up time for the entire study
cohort was 5.3 years for the censored observations. The
median follow-up time was 5.3 years among patients
who received blood transfusions and 5.3 years among
patients who did not undergo have blood transfusions.
Table 1 lists the characteristics of patients in the blood
transfusion and no-transfusion groups before and after
propensity score matching.
Prior to matching, patients who received blood transfu-
sions differed from those who did not have transfusion in
terms of important prognostic factors. Patients who re-
ceived transfusion were more likely to have stage II to III
disease (p = 0.018) compared to patients who did not
undergo transfusion. The transfused patients were also
more likely to have low hemoglobin levels (p < 0.0001).
Matching using the propensity score substantially reduced
the imbalance. None of the variables was significantly dif-
ferent between the transfused patients and non-transfused
patients in the matched cohort.
Recurrence free survival
Among the 599 out of 636 patients with recurrence in-
formation, the median RFS time was of 68.79 (95% con-
fidence interval (CI): 61.4-81.8) months with a RFS rate
at 3 and 5 years of 65% (95% CI: 61-69%) and 54% (95%
CI: 50-59%). The log-rank test showed that age > 66 or
older, BMI 25 or lower, male, high ASA physical status,high cancer stage, ASA physical status, preoperative Hb
lower than 12 g/dL, or receiving chemoterapy and radio-
therapy were associated with worse RFS (Table 2). Also, the
transfused patients had a worse RFS compared to those
non-transfused patients (p = 0.0003). In addition, the num-
ber of units transfused (0, 1–3, 4–9 and more than 10) was
a factor associated with worse RFS (p = 0.001). Tumor size
has a significant impact on RFS from unicovariate Cox pro-
portional hazards model (data not shown). In the multivari-
able Cox regression analysis, blood transfusion was still
significantly associated with worse RFS (p = 0.02, harzard
ratio (HR): 1.55 (95% CI: 1.06-2.27)) with the adjustment of
age, gender, BMI, ASA, cancer stage, and hemoglobin level
in the model (Table 3). In the analysis with the matched co-
hort, the effect of blood transfusion on RFS was not signifi-
cant (p = 0.14) (Table 3, Figure 1).
Overall survival
The OS rate of all patients was 72% (95% CI: 69-76%)
and 62% (95% CI: 58-66%) at 3 and 5 years respectively
with a median OS time of 82.39 months (95% CI: 78.65-
NA). The univariable analysis demonstrated that blood
transfusion was associated with worse overall survival
outcomes (Figure 2A). Other prognostic variables that
had a significant impact on OS from the log-rank test
were age (p < 0.0001), BMI (p = 0.0014), gender (p <
0.0001), ASA score (p = 0.04), cancer stage (p < 0.0001),
number of transfused units (p < 0.0001), preoperative
and postoperative chemoradiation (< 0.0001) and pre-
operative Hb (p = 0.001) (Table 4). In addition, tumor
size had a significant impact on OS from uni-covariate
Table 2 Recurrence free survival (RFS) by patient characteristics
Variable Level N Event Median RFS time
in months (95% CI)
RFS rate at
3 years (95% CI)
RFS rate at
5 years (95% CI)
P-value
All patients 599 277 68.79 (61.4,81.8) 0.65 (0.61,0.69) 0.54 (0.5,0.59)
Age (years) < 66 277 107 81.7 (74.24,NA) 0.69 (0.64,0.75) 0.61 (0.55,0.67) 0.008
> = 66 322 170 56.67 (43.69,68.79) 0.61 (0.56,0.67) 0.49 (0.44,0.55)
BMI < =25 223 115 53.48 (37.42,NA) 0.58 (0.51,0.65) 0.46 (0.4,0.54) 0.02
>25 376 162 75.33 (67.05,NA) 0.69 (0.65,0.74) 0.59 (0.54,0.65)
Gender F 281 114 87.52 (72.34,NA) 0.71 (0.65,0.76) 0.62 (0.56,0.68) 0.0002
M 318 163 53.78 (41.85,68.66) 0.6 (0.55,0.66) 0.47 (0.42,0.54)
ASA 2 63 23 NA (63.24,NA) 0.7 (0.59,0.83) 0.62 (0.5,0.76) 0.04
3 500 230 69.97 (60.35,NA) 0.65 (0.61,0.69) 0.55 (0.5,0.59)
4 35 24 39.13 (20.4,NA) 0.56 (0.42,0.76) 0.38 (0.25,0.59)
Stage 1 332 121 87.19 (81.8,NA) 0.75 (0.71,0.8) 0.64 (0.59,0.7) < 0.0001
2 125 74 48.65 (27.73,66.52) 0.55 (0.46,0.64) 0.43 (0.35,0.53)
3 140 82 31.44 (20.01,67.05) 0.49 (0.41,0.58) 0.4 (0.33,0.5)
Preoperative N 497 222 74.24 (65.54,NA) 0.67 (0.63,0.72) 0.57 (0.52,0.61) 0.001
Hb < 12 g/dL Y 101 55 39.13 (23.75,NA) 0.52 (0.43,0.63) 0.42 (0.33,0.54)
BT N 548 244 74.24 (66.52,7.52) 0.67 (0.63,0.71) 0.57 (0.52,0.61) 0.0002
Y 51 33 23.98 (16.98,55.22) 0.4 (0.28,0.57) 0.29 (0.18,0.45)
Number of units 0 548 244 74.24 (66.52,87.52) 0.67 (0.63 0.71) 0.57 (0.52,0.61) 0.001
Transfused 1-3 31 19 24.34 (10.32,NA) 0.4 (0.25,0.63) 0.32 (0.19,0.55)
4-9 12 8 24.24 (22.21,NA) 0.42 (0.2,0.88) 0.21 (0.06,0.72)
>10 6 5 17.85 (3.45,NA) 0.33 (0.11,1) 0.17 (0.03,1)
Preoperative N 501 217 77.63 (66.69,NA) 0.69 (0.65,0.73) 0.58 (0.53,0.62) < 0.0001
Chemo-radiation Y 98 60 21.71 (13.83,55.22) 0.45 (0.36,0.56) 0.38 (0.29,0.49)
Postoperative Chemo only 132 57 81.8 (60.35,NA) 0.67 (0.59,0.76) 0.58 (0.5,0.68) < 0.0001
Therapy Chemo/Radiation 54 35 34.92 (17.35,74.24) 0.49 (0.36,0.65) 0.39 (0.28,0.56)
None 378 160 75.33 (66.52,NA) 0.69 (0.65,0.74) 0.58 (0.53,0.63)
Radiation only 35 25 20.66 (3.47,51.35) 0.38 (0.25,0.59) 0.27 (0.15,0.46)
P-values from the log-rank test (univariable analysis), p < 0.05 is considered statistically significant. BMI Body mass index. ASA American Society of Anesthesiologist
physical status. Hb Hemoglobin.
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the multivariable Cox regression analysis, blood transfu-
sion was still significantly associated with worse OS,
p = 0.0002, harzard ratio (HR): 2.04 (95% CI: 1.41-2.97))
with the adjustment of age, gender, BMI, ASA, cancer
stage, and hemoglobin level in the model (Table 5).
In the analysis with the matched cohort, the effect of
blood transfusion on OS was still significant (p = 0.035)
(Table 5, Figure 2).Table 3 Association between blood transfusion (Y vs. N) and
Unadjusted (univariate analysis), before matching (E/N = 277/599)
Adjusted for covariates (multivariate analysis)* (E/N = 277/595)
Propensity-matched, stratifying on the matched pair (E/N = 78/135)
*Covariate in the final model included age, gender, BMI, ASA, Stage, and Hb.Discussion
In colorectal cancer patients, a metaanalysis by Amato
and Pescatori demonstrated that blood transfusions are an
independent factor for cancer recurrence [12]. In our
work, we found that perioperative blood transfusions in
the context of NSCLC surgery are associated with shorter
OS; however, this association was not observed for RFS.
Our findings are not fully in line with some of the results
published by other authors [2,14,15,18-20].recurrence free survival
p-value HR 95% CI
0.0003 1.97 1.37 2.84
0.0253 1.54 1.05 2.27















N ( E / N = 26 / 50 )
Y ( E / N = 33 / 50 )
p=0.146
Figure 1 The Kaplan-Meier curve and p-value from stratified Cox proportional hazards model for RFS are depicted in the figure. Our
analysis showed no association between blood transfusion and recurrence free survival.
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fusions did not increase the risk of cancer recurrence or
worsen overall survival after lung cancer resection [21].
Similarly, Berardi et al., and Panagopoulos et al. reported
that perioperative blood transfusions were not an inde-














N ( E / N = 21 / 50 )
Y ( E / N = 30 / 50 )
p=0.035
Figure 2 The Kaplan-Meier curve and p-value from stratified Cox pro
Our analysis showed a statistically significant association between blood traFinally, a retrospective study that included 493 patients
also found no association between blood transfusions and
overall survival after NSCLC cancer surgery [24]. Contrary
to those studies and similar to our findings in terms of OS,
5 retrospectives analysis have shown that blood transfusion
are associated with shorter OS [2,13-15,25]. Importantly, a (months)
48 60 72 84 96
portional hazards model for OS are shown in the figure.
nsfusion and overall survival.
Table 4 Overall survival (OS) by patient characteristics
Variable Level N Event Median OS time
in months (95% CI)
OS rate at
3 years (95% CI)
OS rate at
5 years (95% CI)
P-value
All patients 636 243 82.39 (78.65,NA) 0.72 (0.69,0.76) 0.62 (0.58,0.66)
Age < 66 291 83 NA (NA,NA) 0.8 (0.76,0.85) 0.71 (0.65,0.76) < 0.0001
> = 66 345 160 74.84 (61.17,NA) 0.66 (0.61,0.71) 0.55 (0.5,0.61)
BMI < =25 241 111 77.63 (53.78,NA) 0.65 (0.6,0.72) 0.53 (0.47,0.6) 0.0014
>25 395 132 NA (79.24,NA) 0.77 (0.73,0.81) 0.68 (0.63,0.73)
Gender Female 298 90 NA (NA,NA) 0.81 (0.76,0.86) 0.7 (0.65,0.76) < 0.0001
Male 338 153 69.32 (59.99,NA) 0.65 (0.6,0.71) 0.55 (0.5,0.61)
ASA 2 66 18 NA (77.63,NA) 0.8 (0.71,0.91) 0.72 (0.61,0.85) 0.0405
3 531 203 NA (79.24,NA) 0.72 (0.69,0.76) 0.62 (0.58,0.66)
4 38 22 58.2 (34.33,NA) 0.61 (0.47,0.78) 0.5 (0.36,0.69)
Stage 1 351 104 NA (NA,NA) 0.82 (0.78,0.86) 0.71 (0.66,0.76) < 0.0001
2 131 58 77.63 (62.06,NA) 0.69 (0.62,0.78) 0.58 (0.5,0.68)
3 152 81 45.99 (31.64,81.7) 0.53 (0.46,0.62) 0.45 (0.37,0.54)
Preoperative N 525 188 NA (81.7,NA) 0.75 (0.71,0.79) 0.65 (0.61,0.69) 0.0001
Hb < 12 g/dL Y 110 55 58.51 (37.42,NA) 0.6 (0.51,0.7) 0.48 (0.39,0.59)
Perioperative N 576 207 NA (79.24,NA) 0.75 (0.71,0.79) 0.65 (0.61,0.69) < 0.0001
BT Y 60 36 33.71 (22.5,NA) 0.48 (0.37,0.63) 0.35 (0.24,0.5)
Number of units 0 576 207 NA (79.24,NA) 0.75 (0.71,0.79) 0.65 (0.61,0.69) < 0.0001
Transfused 1-3 36 23 30.39 (19.84,NA) 0.47 (0.33,0.68) 0.32 (0.19,0.53)
4-9 15 8 54.99 (24.24,NA) 0.56 (0.35,0.9) 0.4 (0.21,0.78)
>10 7 4 23.26 (4.76,NA) 0.36 (0.12,1) 0.36 (0.12,1)
Preoperative N 532 187 NA (81.7,NA) 0.75 (0.72,0.79) 0.65 (0.61,0.7) < 0.0001
Chemo-radiation Y 104 56 51.41 (34.03,NA) 0.58 (0.49,0.68) 0.46 (0.37,0.57)
Postoperative Chemo only 137 40 NA (81.8,NA) 0.8 (0.73,0.87) 0.72 (0.65,0.81) < 0.0001
Chemo-radiation Chemo-radiation 55 32 50.85 (34.03,NA) 0.58 (0.46,0.73) 0.43 (0.31,0.6)
None 408 147 NA (75.53,NA) 0.74 (0.7,0.78) 0.64 (0.59,0.69)
Radiation only 35 24 37.52 (23.26,65.05) 0.5 (0.36,0.7) 0.32 (0.2,0.53)
P-values from the log-rank test (univariable analysis), p < 0.05 is considered statistically significant. BMI Body mass index. ASA American Society of Anesthesiologist
physical status. Hb Hemoglobin.
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marizes the current evidence on this topic and highlights
the controversy between blood transfusion and risk of can-
cer recurrence after lung cancer surgery [4].
There are several reasons that might explain these
controversial findings. First, the presence of unknown
confounding factors. Second, the indications for blood
transfusions and the type of lung resection; in particular
the latter (degree and complexity of surgical procedure)Table 5 Association between blood transfusion (Y vs. N) and
Unadjusted (univariate analysis), before matching (E/N = 243/636)
Adjusted for covariates (multivariate analysis)* (E/N = 243/632)
Propensity-matched, stratifying on the matched pair (E/N = 68/135)
*Covariate in the final model included age, gender, BMI, ASA, Stage, and Hb.has been shown to have a significant impact on recurrence-
free survival [26]. Third, it has been suggested that the use
of blood transfusions as a surrogate for correction of low
hemoglobin values (anemia) may have contributed to the
differences amongst the published studies on this topic.
It may very well be that preoperative anemia and the
myelo-recovery from the disease process and thera-
peutic interventions may in fact be the more important
and determining prognostic factor [22]. And fourth, theoverall survival
p-value HR 95% CI
< 0.0001 2.33 1.63 3.32
0.0002 2.04 1.40 2.97
0.035 1.83 1.04 3.24
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regards, our study is particularly different to the rest of the
published studies because we performed a propensity score
matching analysis and we consider this a strength of the
present work. Propensity matching score analysis has be-
come the suggested method to analyze observational data,
in particular in the context of perioperative medicine, be-
cause the technique allows estimating the treatment effect
controlling for covariates such as comorbidities. In our
study, by matching on the propensity score, we eliminated
those transfused patients with no comparable non-
transfused subjects, hence eliminating potential bias in
factors contributing to the decision for perioperative
transfusion [27]. In our study, the standardized differ-
ences for all covariates were lower than 15% in the post-
matching cohort, suggesting substantial reduction of
bias between the two groups.
Our univariate analysis also demonstrated that pre-
operative Hb was associated with poor RFS and OS. It
has been suggested that the degree of anemia is a
marker of myelosuppression in patients receiving che-
moradiation, and in fact, the severity of anemia may be
correlated with tumor response and hence an important
predictor of survival [28]. Paradoxically, low hemoglobin
concentrations may cause tumoral hypoxia which can
trigger adaptive mechanisms that may alter the pheno-
type of the cancer cells turning them more aggressive
[29]. Several studies, even those that did not find an as-
sociation between blood transfusion and NSCLC recur-
rence, have observed that preoperative anemia is a risk
factor for recurrence and it has been hypothesized that
blood transfusions may only represent an intervention to
correct low hemoglobin concentrations [22,23]. In fact,
patients whose hemoglobin levels remained lower than
12 g/dl despite transfusion had worse prognosis, thus
suggesting that the degree of anemia before transfusions,
may be a predictor of survival [22]. This concept is sup-
ported by a study suggesting that after adjusting for pre-
operative anemia, blood transfusion is an independent
factor for recurrence and overall survival in patients with
NSCLC stage 1 cancer [13]. In our study, transfused pa-
tients had significantly lower preoperative Hb concentra-
tion; hence we decided to include this variable in the
matching in order to avoid significant confounding.
Another interesting finding of our study is that the
number of blood transfusions received appeared to be as-
sociated with poor outcomes. There are several possible
reasons that might explain our findings. First, a “dose-
dependent” effect; although a our findings are not in line
with those reported by Keller et al., it is possible to specu-
late that the magnitude of immunosuppression associated
with blood transfusions is greater as the number of units
transfused increases; hence, the likelihood to recur after
surgery [30]. Second, patients with larger tumors andcomplex procedures who are subject to a higher chances
of incomplete tumor resections and postoperative compli-
cations may be also exposed to a higher number of units
transfused, hence, our findings only a reflection of the
magnitude of bulk tumoral disease [13].
Our study has several limitations. First, this is a retro-
spective study, hence there are unknown factors that may
affect the studied outcomes and were not captured in our
data collection (i.e. tumor markers, age of the transfused
units, postoperative complications and cause of death).
Postoperative complications after major thoracic surgery
are known to negatively impact mortality, hence, it is pos-
sible to speculate that in our database those patients trans-
fused might have suffered from more transfusion-related
or unrelated postoperative complications which would
have significantly affected their survival [31]. We were not
able to capture the cause of death of all our patients,
hence our results might have been heavily confounded by
the presence of comorbidities known to have significant
impact on OS. In fact, our univariate and multivariate ana-
lysis indicated a potential association between ASA phys-
ical status and OS; hence, since co-morbidities are part of
the ASA score, we included it in the matching analysis.
Second, we included a heterogeneous group of patients
in regards to the stage of the disease. Four other studies
that analyzed recurrence and mortality in an uniform
group of patients (stage 1) have shown that blood transfu-
sions are in fact an independent factor for poor outcomes
[2,18,23,25]. Interestingly, Ng et al. suggested that the im-
pact of blood transfusion is less evident in patients with
advanced stages of NSCLC because the poor baseline
prognosis of this patients [13]. Third, a major limitation of
the present work is that we included patients who had re-
ceived both leucoreduced and non-leucoreduced pRBCs
during the perioperative period. The impact of leukore-
duced transfusions on NSCLC recurrence and patient sur-
vival is controversial. Ng et al. demonstrated that the
administration of leukodepleted pRBCs was associated
with poorer outcomes than non-transfused patients [13].
Similar results were shown by Panagopoulos et al. suggest-
ing that at least for NSCLC transfusion of pRBCs itself ra-
ther than the leukoreduced status of the unit has a more
significant impact on outcomes [23]. Blood units given
intraoperatively in our institution are typically non-
leucoreduced, while the units dispensed to the patient
floors are non-leukoreduced. Thus a given patient with
multiple perioperative blood transfused may have received
leucoreduced units pre- or postoperatively and non-
leucoreduced blood intraoperatively. We have therefore
not analyzed patients according to the leucoreduction sta-
tus of the blood units received, as it would not have
reflected the current transfusion practice at our institu-
tion. Finally, our conclusion of no significant effect of
pRBC transfusions on RFS after propensity matching
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Cox regression analysis showed an association between
blood transfusion and increased cancer recurrence. It is
possible that the small sample size in the matching cohort
group may have contributed to our results.
Conclusions
The perioperative administration of pRBCs appears not
to be associated with shorter disease-free survival but
with worse overall survival after NSCLC surgery. A ran-
domized controlled trial is needed to support our find-
ings and to elucidate the real impact of perioperative
blood transfusion on cancer recurrence and survival
after lung cancer surgery.
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